Latest Pneumococcal conjugate vaccine Stories
Grant MacKenzie of the MRC Unit in The Gambia and colleagues describe in this week's PLoS Medicine how they set up a population-based surveillance system to assess the impact of pneumococcal conjugate vaccines (PCVs) on invasive pneumococcal disease (IPD) and radiological pneumonia in children in The Gambia.
Seventy-seven percent of Washington state pediatricians report that they are sometimes or frequently asked to provide alternative childhood vaccine schedules for their patients.
Vaccines against the primary cause of deaths from pneumonia in developing countries could save millions of lives and are highly cost-effective.
Vaccinating young children against pneumonia in turn will protect the entire community.
Researchers at Albert Einstein College of Medicine of Yeshiva University have discovered how a novel type of antibody works against pneumococcal bacteria.
SCHLIEREN, Switzerland, June 15, 2011 /PRNewswire/ -- GlycoVaxyn AG, a leader in the development of conjugate vaccines, today announced that it will host its Second Annual Science Day to discuss challenges and opportunities in vaccine development on June 16-17, 2011, in Cannes, France.
SAN DIEGO, May 17, 2011 /PRNewswire/ -- Pfenex Inc.'s Reagent Proteins division announced today that it has submitted a Biologics Master File (BMF) to the United States Food and Drug Administration for its cGMP grade CRM197 carrier protein to support the development of conjugate vaccine products by its partners. Reagent Proteins is supplying cGMP grade CRM197 carrier protein to multiple partners in support of their novel conjugate vaccine development efforts.
SWIFTWATER, Pa., April 22, 2011 /PRNewswire/ -- Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announced today that the U.S.
- An uxorious, effeminate, or spiritless man.
- A timorous, cowardly fellow.